The complex interplay between the multiple pathogenic factors that underlie uremic bleeding syndrome is yet to be fully elucidated. As such, guidelines on management of this complication of chronic renal failure are lacking. Here, data from clinical trials of dialysis, erythropoietin, cryoprecipitate, desmopressin and conjugated estrogens have been used to develop a treatment algorithm. This decision aid is accompanied by answers to questions that commonly arise during management of uremic bleeding.
- Stephanie J Hedges
- Sarah B Dehoney
- Anthony J Busti